Asylum seekers and healthcare

UK - Over 100,000 asylum seekers have been relocated throughout London and England's southeast, to spread the cost of their medical care.

However, because many of these people are from countries where HIV and AIDS are rife, many doctors have pointed out that their dispersal may lead to increased HIV transmission in the UK. Additionally, the relocations might not only harm those who might contract the disease, but the asylum seekers themselves, i.e. those already undergoing medical investigations, or beginning antiretroviral therapy, or alternative therapy after drug regimes had failed, or whose care involves multiple medical specialities. Dispersal should also not be considered for those with full-blown AIDS.

A survey of 56 employees in sexual health clinics in London revealed concern that dispersal of asylum seekers was often done within just 48 hours of their arrival, and often without the transfer of their medical details. Only three centres reported appropriate transfer of care.

The doctors argued that before the decision to disperse, the National Asylum Support Service (NASS) should consider expert medical advice, as well as consider the impact on the infrastructure and staffing of sexual health clinics taking over these cases.

However, the Home Office said that the NASS did consider medical conditions and dispersed asylum seekers with hi considerations into there was no evidence that dispersal increased the likelihood of onward transmission of HIV to others, and it was working with HIV or AIDS to areas with suitable medical services.

01.09.2004

Read all latest stories

Related articles

Photo

Article • Treating Ebola

An isolation unit flying on 60-metre wings

The ‘Robert Koch’ plane for medical evacuations (MedEvac) is the winged equivalent of a German hospital isolation ward. Within it, medics with viral haemorrhagic fever while working on the Ebola…

Photo

Article •

The ‘sepsis team’

‘We are all aware of the importance of early diagnosis and rapid appropriate treatment of patients with severe sepsis. Yet, many patients still do not receive satisfactory early management and the…

Photo

Article • Regulatory challenges for AI-based diagnostics

Further IVDR changes: a step in the right direction, but…

New changes made to the timetable for the In vitro Diagnostic Medical Device Regulation (IVDR) across Europe could have a significant impact on manufacturers and users, an expert points out. While…

Related products

Alsachim - Dosimmune immunosupressant Alsachim – kit (CE-IVD or RUO)

Clinical Chemistry

Alsachim - Dosimmune immunosupressant Alsachim – kit (CE-IVD or RUO)

Alsachim, a Shimadzu Group Company
Alsachim – Dosimyco immunosupressant reagent kit (RUO)

Clinical Chemistry

Alsachim – Dosimyco immunosupressant reagent kit (RUO)

Alsachim, a Shimadzu Group Company
Alsachim – Dosinaco anticoagulant reagent kit (RUO)

Clinical Chemistry

Alsachim – Dosinaco anticoagulant reagent kit (RUO)

Alsachim, a Shimadzu Group Company
ASP Lab Automation – SortPro Sample sorter

Sample Processing

ASP Lab Automation – SortPro Sample sorter

ASP Lab Automation AG
Beckman Coulter – Access 2 Immunoassay System

Immunoassays

Beckman Coulter – Access 2 Immunoassay System

Beckman Coulter Diagnostics
Subscribe to Newsletter